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ABSTRACT
Background. Chemotherapy treatment induces parenchy-
mal changes that potentially affect imaging of CRLM. The
purpose of this meta-analysis was to provide values of
diagnostic performance of magnetic resonance imaging
(MRI), computed tomography (CT), fluorodeoxyglucose
positron emission tomography (FDG-PET), and FDG-PET/
CT for preoperative detection of colorectal liver metastases
(CRLM) in patients treated with neoadjuvant chemotherapy.
Methods. A comprehensive search was performed for ori-
ginal articles published from inception to 2011 assessing
diagnostic performance of MRI, CT, FDG-PET, or FDG-
PET/CT for preoperative evaluation of CRLM following
chemotherapy. Intraoperative findings and/or histology were
used as reference standard. For each imaging modality we
calculated pooled sensitivities for patients who received
neoadjuvant chemotherapy as well as for chemonaive
patients, defined as number of malignant lesions detected
divided by number of malignant lesions as confirmed by the
reference standard.
Results. A total of 11 papers, comprising 223 patients with
906 lesions, were included. Substantial variation in study
design, patient characteristics, imaging features, and refer-
ence tests was observed. Pooled sensitivity estimates of MRI,
CT, FDG-PET, and FDG-PET/CT were 85.7%
(69.7–94.0%), 69.9% (65.6–73.9%), 54.5% (46.7–62.1%),
and 51.7% (37.8–65.4%), respectively. In chemonaive
patients, sensitivity rates were 80.5% (67.0–89.4%) for CT,
81.3% (64.1–91.4%) for FDG-PET, and 71.0% (64.3–
76.9%) for FDG-PET/CT. Specificity could not be calcu-
lated because of non-reporting of ‘‘true negative lesions.’’
Conclusion. In the neoadjuvant setting, MRI appears to be
the most appropriate imaging modality for preoperative
assessment of patients with CRLM. CT is the second-best
diagnostic modality and should be used in the absence of
MRI. Diagnostic accuracy of FDG-PET and PET-CT is
strongly affected by chemotherapy.
One in two colorectal cancer patients develop liver
metastases at some point during their disease.1,2 The only
potentially curative option for these patients is surgical
resection of their colorectal liver metastases (CRLM), after
which 5 years survival probabilities of 25–58% can be
achieved.3–5 Still, 80–85% of CRLM patients are not eligible
for liver surgery because of extensive intrahepatic metastatic
lesions or the presence of extrahepatic disease.6 Neoadjuvant
chemotherapy is increasingly applied with the aim to
downsize tumors in patients with initially unresectable dis-
ease to attain a resectable situation.7–9 Around 15–20% of
these patients have their tumors rendered resectable fol-
lowing neoadjuvant chemotherapy and show similar survival
rates as patients with initially resectable tumors.7,10,11
Accurate imaging of the liver following neoadjuvant
chemotherapy is crucial for optimal selection of patients
eligible for surgical resection. However, neoadjuvant che-
motherapy may impair lesion detection and underestimate
lesion size, as a result of the occurrence of intraparen-
chymal changes.12–15 As a result, patients whose tumors
were considered resectable on preoperative imaging may
turn out to have unresectable tumors during surgery.
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Different imaging modalities are used in clinical practice
for preoperative imaging of liver metastases. In the absence
of neoadjuvant chemotherapy, contrast-enhanced computed
tomography (CE-CT) and contrast-enhanced magnetic res-
onance imaging (CE-MRI) have been shown to be accurate
diagnostic tools for preoperative imaging of CRLMs, with
sensitivity rates varying from 60 to 90%.16–19 Fluorode-
oxyglucose positron emission tomography (FDG-PET) may
not be very informative on the anatomical location of
intrahepatic lesions, but is highly sensitive for detection of
intrahepatic lesions as well as extrahepatic disease.20,21 In
an attempt to maintain high sensitivity while improving
anatomical localization, CT and FDG-PET have now been
combined into FDG-PET/CT.21
In the neoadjuvant setting, however, scientific evidence
on the accuracy of the various imaging modalities for
preoperative imaging of CRLMs is limited and ambiguous.
We conducted a systematic review and meta-analysis of the
literature in order to identify the optimal imaging modality
for preoperative evaluation of patients with CRLM treated
with neoadjuvant chemotherapy.
MATERIALS AND METHODS
Search strategy and collection of data were performed
according to the guidelines of preferred reporting items for
systematic reviews and meta-analyzes (PRISMA) 2009.22
Data Sources and Searches
A comprehensive literature search was performed from
inception to May 2011 by one observer (C.K.) for articles
assessing the diagnostic accuracy of CT, MRI, FDG-PET,
or FDG-PET/CT for preoperative evaluation of CRLM
after neoadjuvant chemotherapy. The literature search was
performed in MEDLINE and EMBASE and included
synonyms for CRLM (e.g., CRLM, hepatic metastases),
chemotherapy (e.g., chemotherapy, neoadjuvant treat-
ment), and the different imaging modalities (e.g., computed
tomography, CT, magnetic resonance imaging, MRI, pos-
itron emission tomography, FDG-PET, FDG-PET/CT,
PET-CT). In addition, we searched reference lists of
included full text articles.
Study Selection Our search targeted articles based on the
following inclusion criteria: patients were diagnosed with
initially unresectable CRLM, patients should have been
treated with neoadjuvant chemotherapy for downsizing in
order to render their tumors resectable, patients were
intended to undergo liver surgery, patients underwent post-
chemotherapy and pre-operative imaging of the liver, and
papers should present original data. Review articles, letters,
comments, case reports (n B 10), and animal studies were
eliminated. Screening on title and abstract was initially
performed using the aforementioned selection criteria. Of
the papers that were found eligible based on title and
abstract screening, full text was reviewed to further decide
on suitability for inclusion in this study.
Quality Assessment and Data Extraction Two observers
(C.K. and H.M.V.) independently performed a critical
appraisal of the remaining full text articles and extracted
relevant data using a standardized form. After independent
review was performed by both authors, a consensus reading
was performed to discuss any disagreements in order to
come to a final conclusion.
For each study, we extracted basic information on year
of publication, characteristics of the study population (age,
male-to-female ratio, site of primary tumor, proportion of
patients treated with chemotherapy), and study design.
Quality of the studies was quantified with a modified ver-
sion of the quality assessment of diagnostic accuracy
studies (QUADAS) tool of which four items were elimi-
nated (i.e., irrelevant because of the inclusion and
exclusion criteria) and four items were added (Fig. 1).23
The imaging technique of each study was recorded. For
studies using CT, data on use of contrast material, amount
of iodine, system type, slice collimation, and imaging
phases (multiple or single-phase) were assessed. For MRI,
the magnetic field strength, use of contrast material,
sequences, and slice collimation were recorded. For FDG-
PET system type, tracer specifics, scanning time, and
duration of fasting time were extracted, and for FDG-PET/
CT features similar to those for FDG-PET and CT were
obtained.
To ensure adequate assessment of lesion detection,
assessment had to be performed by a radiologist. Studies
where information on lesion detection was extracted from
hospital records (and not from the actual images) were
excluded. To verify the presence of CRLM, we used a
composite reference standard, consisting of (1) follow-up
imaging for patients who did not undergo surgery, (2)
intraoperative palpation, intraoperative ultrasound, and
follow-up in patients who underwent surgical exploration
without resection (preoperative unresectable situation), and
(3) histological examination of the surgical specimen in
patients who underwent surgical resection.
Total numbers of benign and malignant lesions as
detected by imaging were extracted. Similarly, we extrac-
ted the total number of benign and malignant lesions
detected by the reference standard. In order to determine
the diagnostic performance of each imaging modality, the
number of true positive, false positive, true negative, and
false negative results were extracted from the article or
calculated from the data (if possible). All parameters were
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recorded on a lesion level, for patients treated with and
without neoadjuvant chemotherapy. Because of the paucity
of studies reporting data on a patient level, we deemed
calculating endpoints on a per-patient level to be not
justifiable.
True positive lesions were defined as malignant lesions
diagnosed on imaging and confirmed by the reference
standard (i.e., follow-up imaging, preoperative US and
palpation, or histology). False positive lesions were defined
as lesions diagnosed as malignant on imaging that turned
out to be benign by the reference standard. False negative
lesions were defined as lesions characterized as benign or
missed by imaging that turned out to be malignant based on
the reference standard.
We were not able to extract data on true negative
lesions, as none of the articles reported data about the
detection of benign lesions that were confirmed by the
reference standard (true negatives). Sensitivity was calcu-
lated as true positive lesions/(false negative lesions ? true
positive lesions).
Data Analysis Sensitivities were calculated for each
imaging modality (CT, PET-CT, FDG-PET, and MRI)
and separately for patients who had received chemotherapy
and those who had not. Sensitivities were logit-transformed
to improve an approximate normal distribution and then
pooled. Only outcomes from the same modality and with
the same chemotherapy treatment status were combined.
The I2 heterogeneity statistic (estimated proportion of
unexplained interstudy variance) was used to assess
whether random or fixed effects were appropriate for
pooling, with a 25% threshold chosen above which to apply
random effects.24,25 Antilogit transformations of the
resulting (pooled) sensitivities were obtained. Putatively
explanatory study and population factors were assessed
using mixed-effects meta-regression. Funnel plots were
generated to test for publication bias. Because of the
absence of reported numbers of ‘‘true negative’’ and ‘‘false
positive’’ lesions we were unable to calculate specificity.
RESULTS
The literature search resulted in 2,491 unique references,
85 of which were potentially eligible for inclusion based on
their title and/or abstract. Cross-referencing of these papers
yielded four additional articles. Full text screening resulted
in exclusion of another 71 articles. The remaining 18
articles met all inclusion criteria and were selected for
critical appraisal (Fig. 2).
Critical Appraisal and Study Description
Critical appraisal of the 18 articles by two observers led to
exclusion of another 7 papers, because: patients receiving
neoadjuvant chemotherapy could not be distinguished from
patients without chemotherapy (n = 2), data quality was
* FP: false positive, ?: no results or results unclear, -: no. Grey boxes present positive results. 
FIG. 1 Results of critical appraisal
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poor [i.e., retrospective data collection of CT data from
hospital files without re-evaluation of the images (n = 1)],
data were not presented on a per-lesion basis (n = 4).26–31
Thus, a total of 11 articles were included in our meta-analysis.
All studies were published within the last 10 years. Of
the 11 studies, 6 were prospective cohort studies; the
remaining 5 articles were retrospective cohort studies.
Critical appraisal of quality showed that most articles
adequately described in ‘‘Materials and Methods’’ (Fig. 1).
All studies applied lesion mapping to ensure correct lesion
comparison between preoperative imaging and the refer-
ence standard. A total of 906 lesions in 223 patients treated
with neoadjuvant chemotherapy and 450 lesions in 265
chemonaive patients were included. Distribution of
lesions detected by the different reference standards was as
follows: of the patients treated with neoadjuvant chemo-
therapy, 835 of the 906 lesions (91.2%) were confirmed by
intraoperative ultrasound followed by resection (histology),
and 71 lesions (8.8%) were confirmed by follow-up
imaging only. All 835 lesions in chemonaive patients were
confirmed by intraoperative ultrasound followed by resec-
tion (histology). Baseline characteristics of these 11 studies
are presented in Table 1.
Imaging Features and Evaluation Computed tomography
was evaluated in five studies.32–36 A helical system was used
in one study, multidetector CT systems in two studies, a
single slice system in one study, and one study did not report
on the system used. Intravenous contrast was used in four
studies (non-ionic agents in three studies), and one study did
not report on the use of a contrast agent. Also, four studies
reported on using multiple phase imaging. Section thickness
(2–5 mm) was described in three studies.
Magnetic resonance imaging was evaluated in three
studies.34,36,37 Of these, two studies used 1.5 Tesla systems,
and one study combined 1.5 and 3.0 Tesla systems. Gad-
olinium-based contrast was used for dynamic scanning in
one study, and two studies used superparamagnetic iron
oxides (SPIOs) or other liver-specific contrast.
Accuracy of FDG-PET was assessed in six studies.21,33,
35,37–39 All studies used different scanning systems; three
studies reported a fasting period of 4–6 h. The amount of
tracer varied between 250 and 666 MBq. All six studies
reported an interval between contrast injection and scan-
ning of 60–120 min. Only two studies reported on the
duration of scanning time (3–4 min per bed position in 6–7
bed positions).
2406 articles excluded based on







Screening title and abstract for
potentially relevant articles
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71 articles excluded based on 
the following exclusion criteria:
• No data on primary or 
   secondary outcome
• Results based on combination
   of imaging modalities and 
   cannot be extracted
• No surgically treated patients
• Palliative chemotehrapy seting 
   instead of neoadjuvant setting
7 articles were excluded 
following critical appraisal of 
2 blinded readers:
• Not sufficient information
   (n = 2)
• Insufficient reference standard
   (n = 1)
• Data were not presented on a 
   per-lesion basis (n = 4)
FIG. 2 Flowchart showing the
multistep process of identifying articles
that were suitable for this meta-analysis
for evaluation of CRLM after
neoadjuvant chemotherapy
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The effectiveness of PET-CT for detection of CRLM
was assessed in two studies.40,41 Only limited information
on the PET-CT protocol was reported. Both studies used
Discovery LS PET/CT systems (GE Medical Systems).
One study reported on a fasting duration of 4–6 h and use
of 370 MBq FDG. One study did not report on the CT
protocol. The other study performed a single-phase non-
contrast-enhanced CT prior to the PET scan.
All studies used intraoperative ultrasound to confirm the
presence of CRLM and to detect any additional lesions,
and all studies considered histological examination to be
the primary reference standard. In patients who turned out
to have unresectable disease during surgery, intraoperative
ultrasound was used as reference standard. In three studies,
which included patients who were deemed unresectable on
preoperative evaluation, follow-up imaging was used to
confirm the presence of CRLM in the non-operable patients
by assessing lesion growth over time.30,36,37
For patients treated with neoadjuvant chemotherapy,
relevant data were available for 3, 5, 6, and 2 studies on
MRI, CT, FDG-PET, and PET-CT, respectively. A heter-
ogeneous distribution of sensitivities was observed for
MRI, FDG-PET, and PET-CT (I2 [ 25%), while the sen-
sitivity distribution of CT was homogeneous (I2 = 6.75%).
Pooled sensitivity estimates were 85.7% (69.7–94.0%) for
MRI, 69.9% (65.6–73.9%) for CT, 54.5% (46.7–62.1%) for
FDG-PET, and 51.7% (37.8–65.4%) for PET-CT (Fig. 3).
In the chemotherapy-naive setting, relevant data were
available for 2, 4, and 2 studies on CT, FDG-PET, and
PET-CT, respectively. Homogeneous sensitivity distribu-
tion was seen for PET-CT (I2 = 0%), while CT and FDG-
PET showed heterogeneous sensitivity distribution. Pooled
sensitivities were 80.5% (67.0–98.4%) for CT, 81.3%
(64.1–91.4%) for FDG-PET, and 71.0% (64.3–76.9%) for
PET-CT. No studies reported on diagnostic performance of
MRI in chemonaive patients.
Mixed-effect meta-regression analysis showed that dif-
ferences in sensitivity rates for the various imaging modalities
were not explained by study and population variables (i.e.,
age, gender, synchronous/metachronous CRLM).
Publication Bias Visual inspection of the funnel plots did
not show any signs of gross publication bias.42
DISCUSSION
Accurate preoperative imaging of CRLM is crucial for
optimal selection of patients suitable for surgery. With this
meta-analysis we show that according to the currently
available evidence, MRI is the preferable imaging modality
for evaluation of CRLM in the neoadjuvant setting, with a
pooled sensitivity of 85.7%. However, it has to be taken
into account that this estimate is based on a limited number
of studies and that SPIO contrast agents were used in two
of these diagnostic studies, while this contrast agent is
rarely used in current clinical practice because of signifi-
cant side effects and high costs. Furthermore, this meta-
analysis showed that in the absence of MRI, CT is the best
alternative with a pooled sensitivity of 69.9%. Both FDG-
PET and PET-CT, which perform rather well in chemo-
naive liver metastases, have a low diagnostic performance
in the neoadjuvant setting.

























Akhurst et al.38 2005 FDG-PET 42 13 110 41 21/21 61 (30–78) nd nd
Lubezky et al.35 2007 CT ? FDG-PET 75 48 155 122 53/22 nd nd 51/24
Rappeport et al.21 2007 FDG-PET 35 4 71 14 16/19 62 (33–74) nd nd
Carnaghi et al.33 2007 CT ? FDG-PET 19 19 65 65 12/7 61 (41–79) 12/7 14/5
Ramos et al.41 2008 PET-CT 63 17 125 70 41/22 62 (38–78) 31/32 nd
Angliviel et al.32 2009 CT 92 30 270 204 33/59 nd 49/43 32/60
Adie et al.40 2009 PET-CT 74 21 232 87 50/24 64 (–) nd nd
Bacigalupo et al.37 2009 MRI ? FDG-PET 19 19 136 136 11/8 61 (28–74) nd nd
Spatz et al.39 2010 FDG-PET 34 17 62 37 27/7 64 (28–82) nd 27/7
Kulemann et al.34 2010 CT ? MRI 20 20 51 51 12/8 64 (52–77) nd nd
van Kessel et al.36 2011 CT ? MRI 15 15 79 79 5/10 60 (48–71) nd nd
Total 488 223 1,356 906 542/344 62 (28–82)
nd not defined in the article
a Numbers in parentheses are ranges
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The negative impact of neoadjuvant chemotherapy on
the diagnostic performance of the various imaging tech-
niques was most obvious for FDG-PET and PET-CT,
where sensitivity rates decreased from 81.3 and 71.0%,
respectively, in chemonaive patients to 54.5 and 51.7%,
respectively, in patients treated with chemotherapy. This
was a rather unexpected finding, especially for PET-CT.
This may be explained by, firstly, both PET-CT studies
included in this meta-analysis were of small sample size
and, secondly, because sensitivity results in chemonaive
patients were also rather low in both studies. These results
might improve in future studies as PET-CT has been
introduced and optimized during the past years. One reason
behind the chemotherapy-induced decrease in diagnostic
performance of FDG-PET and PET-CT may include
induced necrosis, which may give initially solid metastases
a more cystic appearance. MRI and CT might still visualize
these lesions during the arterial phase in the form of rim
enhancement. On FDG-PET, however, there is no FDG-
uptake in areas with necrosis, and therefore lesions are not
visualized.43 Another explanation could be that neoadju-
vant chemotherapy reduces the average size of CRLM, and
FDG-PET is known to have a lower sensitivity for detec-
tion of subcentimeter lesions than CT or MRI.18,44,45 In
addition, chemotherapy reduces metabolic activity of can-
cer cells [in particular the activity of the glycolytic
hexokinase enzyme (GLUT-1 transporter) that collects
FDG], which may hamper visualization of the lesions on
PET.38 CT and MRI imaging is not affected by this
phenomenon.
The diagnostic performance of CT was also affected by
neoadjuvant chemotherapy, albeit to a lesser extent than
that of FDG-PET and PET-CT. A mechanism behind this
observation might be that neoadjuvant chemotherapy
causes changes of the liver parenchyma, such as steato-
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FIG. 3 Forest plots showing pooled
sensitivities for MRI, CT, FDG-PET,
and PET-CT on a lesion level. a Results
are displayed for the patients who
received neoadjuvant chemotherapy.
b Results are displayed for patients
without neoadjuvant chemotherapy
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(oxaliplatin).12,15,46 For CT it has been shown that neoad-
juvant chemotherapy results in a lower density of the liver
parenchyma and less contrast enhancement, leading to a
decreased liver-to-lesion contrast, thereby hindering the
detection, characterization, and delineation of lesions.14,32
Our meta-analysis shows that MRI has the highest
diagnostic performance in the neoadjuvant setting. How-
ever, two of the three studies that were identified used
SPIO contrast agents. SPIO agents have been replaced
largely by gadolinium-based agents since SPIOs are costly
and require an extensive scanning time, and side effects
frequently occur.47 Currently, gadolinium-based agents and
liver-specific agents such as Gd-EOB-DTPA (Primovist)
are used in routine clinical care for evaluation of CRLM.
The sensitivity of gadolinium-based agents for detection of
CRLM in chemotherapy-naive patients is about 80%.18
However, only one study assessed the use of gadolinium-
enhanced MRI for detection of CRLM after chemotherapy,
and in this study a sensitivity of 72.2% was observed.36
Data on the performance of liver-specific agents such as
Gd-EOB-DTPA (Primovist) for detection of CRLM after
chemotherapy are lacking, although in nontreated patients
high sensitivities for detection of CRLM up to 95% have
been reported.48–51 As the diagnostic performance of MRI
is strongly dependent on the type of contrast agent used,
further research on this imaging modality using the cur-
rently available contrast agents in patients with
chemotherapy treatment is warranted. These studies might
show even better diagnostic performance for MRI in the
neoadjuvant setting than was observed in this meta-
analysis.
We acknowledge that our meta-analysis suffers from
several limitations. No numbers of true negative and false
positive lesions could be extracted reliably in the majority
of studies, and therefore specificity could not be calculated.
However, accurate characterization of benign lesions is
essential, as overestimation of liver lesions (i.e., rating a
benign lesion as malignant) can lead to the incorrect
decision of omitting surgery. In a previous study, our group
has shown MRI to be superior to CT in differentiating
between CRLM and benign lesions as CT was more likely
to overestimate the number of CRLM.36 Most articles did
not incorporate follow-up data in their reference standard,
which may have led to overestimation of sensitivity rates,
as lesions that were missed in the non-operated liver seg-
ments are unaccounted for.52 However, studies reporting
on patients who did not receive resection following che-
motherapy because of unresectability, but did receive
follow-up imaging to confirm the presence of CRLM, were
included in this meta-analysis.
Although there are numerous studies assessing patients
with metastatic colorectal cancer, only 11 studies were
eligible for inclusion in this meta-analysis. This was mainly
because the majority of studies assessing diagnostic accu-
racy of imaging modalities for detection of CRLM
included chemonaive patients only or did not separately
report on patients with and without chemotherapy.
Finally, there were insufficient data to perform a meta-
analysis on an individual patient level. Still, per-patient-
based data are not pertinent for determining the diagnostic
value of the different imaging modalities in preoperative
evaluation of CRLM. However, in addition to lesion-based
sensitivity data, data on resection outcome by imaging
modality would be of great clinical relevance. Although we
consider this to be a limitation of this meta-analysis, it is a
reflection of the currently available evidence as data on
which imaging modality results in the best resection out-
come are currently lacking in the neoadjuvant setting.
Therefore, a trial comparing contrast-enhanced CT and
gadolinium-enhanced or liver-specific contrast-enhanced
MRI would be appropriate. The design of this trial should
not only allow for assessment of lesion detection and
characterization, but also for lesion localization and
resection strategy, in order to determine which imaging
modality most accurately determines treatment strategy.
CONCLUSION
The results of this meta-analysis suggest that MRI is the
most appropriate imaging modality for preoperative
detection of CRLM in patients treated with neoadjuvant
chemotherapy. CT is the second-best diagnostic modality
and should be used in the absence of MRI. FDG-PET and
PET-CT, which perform well for imaging of chemonaive
CRLM patients, should be avoided for preoperative eval-
uation of patients in the neoadjuvant setting.
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